Medizinische Klinik und Poliklinik IV, Klinikum der Universität, Ludwig-Maximilians-Universität, Munich, Germany.
Departments of Medicine and Neurological Surgery and Pituitary Center, Oregon Health & Science University, Portland, Oregon.
JAMA. 2023 Jul 11;330(2):170-181. doi: 10.1001/jama.2023.11305.
Cushing syndrome is defined as a prolonged increase in plasma cortisol levels that is not due to a physiological etiology. Although the most frequent cause of Cushing syndrome is exogenous steroid use, the estimated incidence of Cushing syndrome due to endogenous overproduction of cortisol ranges from 2 to 8 per million people annually. Cushing syndrome is associated with hyperglycemia, protein catabolism, immunosuppression, hypertension, weight gain, neurocognitive changes, and mood disorders.
Cushing syndrome characteristically presents with skin changes such as facial plethora, easy bruising, and purple striae and with metabolic manifestations such as hyperglycemia, hypertension, and excess fat deposition in the face, back of the neck, and visceral organs. Cushing disease, in which corticotropin excess is produced by a benign pituitary tumor, occurs in approximately 60% to 70% of patients with Cushing syndrome due to endogenous cortisol production. Evaluation of patients with possible Cushing syndrome begins with ruling out exogenous steroid use. Screening for elevated cortisol is performed with a 24-hour urinary free cortisol test or late-night salivary cortisol test or by evaluating whether cortisol is suppressed the morning after an evening dexamethasone dose. Plasma corticotropin levels can help distinguish between adrenal causes of hypercortisolism (suppressed corticotropin) and corticotropin-dependent forms of hypercortisolism (midnormal to elevated corticotropin levels). Pituitary magnetic resonance imaging, bilateral inferior petrosal sinus sampling, and adrenal or whole-body imaging can help identify tumor sources of hypercortisolism. Management of Cushing syndrome begins with surgery to remove the source of excess endogenous cortisol production followed by medication that includes adrenal steroidogenesis inhibitors, pituitary-targeted drugs, or glucocorticoid receptor blockers. For patients not responsive to surgery and medication, radiation therapy and bilateral adrenalectomy may be appropriate.
The incidence of Cushing syndrome due to endogenous overproduction of cortisol is 2 to 8 people per million annually. First-line therapy for Cushing syndrome due to endogenous overproduction of cortisol is surgery to remove the causative tumor. Many patients will require additional treatment with medications, radiation, or bilateral adrenalectomy.
库欣综合征被定义为血浆皮质醇水平持续升高,并非由生理病因引起。尽管库欣综合征最常见的原因是外源性类固醇使用,但由于皮质醇内源性过度产生导致的库欣综合征的估计发病率为每年每百万人 2 至 8 人。库欣综合征与高血糖、蛋白质分解代谢、免疫抑制、高血压、体重增加、神经认知改变和情绪障碍有关。
库欣综合征的特征性表现为皮肤变化,如面部多血质、易瘀伤和紫色条纹,以及代谢表现,如高血糖、高血压和面部、颈后和内脏器官脂肪过度沉积。库欣病是由良性垂体肿瘤分泌过量促皮质素引起的,在由内源性皮质醇产生引起的库欣综合征患者中约占 60%至 70%。对可能患有库欣综合征的患者的评估首先从排除外源性类固醇使用开始。通过 24 小时尿游离皮质醇试验、深夜唾液皮质醇试验或评估在接受夜间地塞米松剂量后次日清晨皮质醇是否被抑制来进行皮质醇升高的筛查。血浆促皮质素水平有助于区分肾上腺性皮质醇增多症(促皮质素受抑制)和促皮质素依赖性皮质醇增多症(中至高促皮质素水平)。垂体磁共振成像、双侧岩下窦取血、肾上腺或全身成像有助于识别皮质醇增多症的肿瘤来源。库欣综合征的治疗从切除内源性皮质醇过度产生的来源的手术开始,然后使用包括肾上腺类固醇生成抑制剂、针对垂体的药物或糖皮质激素受体阻滞剂的药物进行治疗。对于对手术和药物治疗无反应的患者,放射治疗和双侧肾上腺切除术可能是合适的。
由于皮质醇内源性过度产生导致的库欣综合征的发病率为每年每百万人 2 至 8 人。由于皮质醇内源性过度产生导致的库欣综合征的一线治疗方法是手术切除致病肿瘤。许多患者将需要额外的药物、放射或双侧肾上腺切除术治疗。